A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)

Sponsor:

Alliance for Clinical Trials in Oncology

Sponsor Study ID:

A031702

CTO #:

103168

NCT Number:

NCT03866382

Phase:

II

Protocol Type:

Treatment

Age Group:

Adults

Disease Sites:

Bladder; Kidney; Other Male Genital; Other Urinary; Prostate

Study Objectives:

This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that have spread to other places in the body. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib, nivolumab, and ipilimumab may work better in treating patients with genitourinary tumors that have no treatment options compared to giving cabozantinib, nivolumab, or ipilimumab alone.

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)